Clinical Trials · NCT03562130

Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients

CompletedPhase 4Teduglutide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
25
Start date
Jul 2018
Locations
1 site, France
Primary endpoint
Decrease in parenteral nutrition: Parenteral Nutrition/Resting Energy Expenditure (PN/REE)
View Teduglutide compound reference